

Annual Report of ICMR (FY 2025-26): ICMR Institutes

Summary Sheet

Parameter	Details
Institute Name	ICMR National Institute of Child Health Research
Reporting Year	April 2025 – March 2026
Total Projects Received	Intramural Grants from ICMR Completed: 01/ Ongoing: 03/ New: 01 Grants other than ICMR Completed: 03 / Ongoing:03/ New: 0
ICMR Institute Research Outcome during 2025-2026 (Publication Equivalents)	
<i>Research publication, Total Number:</i> a publication in indexed peer-reviewed journal reporting results or methods of primary research, or a systematic review and meta-analysis	38
<i>High scientific impact, Total Number:</i> a research publication that has received 100 or more citations, or is published in a journal with an Impact Factor of 10 or more	0
<i>Clinical care/public health impact, Total Number:</i> a research publication/output that has resulted in a documented change in national or international clinical care/public health guidelines	0

<i>Patents: total number of national or international granted patents</i>	1 applied
<i>Health technology developed, Total Number: A new health technology that has been used in limited settings, such as research or surveillance</i>	1
<i>Health technology developed and commercialized, Total Number: A new health technology that has been commercialized and used at scale</i>	0
Health technology developed by Industry validated by ICMR Institute, Total Number	0

The total number for each parameter of PE should corroborate with the details provided in the form below

I-Detailed Information Template: General

A) Information on field units/field stations

S. No.	Name of the centre and Place	Main activities
1	MRHRU, Bhunga. Hoshiarpur (Punjab)	Conducting population-based health surveys, epidemiological studies, implementation research on diseases prevalent in the local area (communicable and non-communicable diseases), and transferring new technologies to rural systems.
2	MRHRU, Khag, Budgam (J&K)	Conducting population-based health surveys, epidemiological studies, implementation research on diseases prevalent in the local area (communicable and non-communicable diseases), and transferring new technologies to rural systems.

B) Information on Human Resources (as on 31st March 2026)

Cadre	Number (Regular)	Number (Contractual/Project)	Number (Consultants)
Scientific Staff	24	5	-
Technical Staff	32	46	-
Administrative Staff	14	5	-

For regular positions, segregate on the basis of gender & category distribution

Cadre	Gender Distribution			Category Distribution				
	Male	Female	Others	Gen	OBC	ST	SC	EWS
Scientific Staff	12	12	-	19	2	1	2	-
Technical Staff	25	7	-	19	5	2	6	-
Administrative Staff	9	5	-	7	3	0	3	1

C) Significant/ notable contributions in research last year

- Novel Findings (First in the World/ India), e.g., vectors, pathogens, strains, etc.-

First study in India -Comparative Proteomic analysis to discover novel plasma biomarkers for early detection, surveillance and prognostication of Atrial fibrillation in patients with Rheumatic heart disease.

- Identified a potential biomarker candidate: Apoprotein A4 with significant differential expression amongst Rheumatic Heart Disease patients with Atrial fibrillation, as compared to those with Normal Sinus Rhythm and Healthy controls.
- New Health Technologies
 - Diagnostics- A novel DBS (Dried blood spot) based kit for leukemia transcript determination has been applied for patents in the Indian Patent Office. A multicentric field validation study has been initiated by ICMR- ref NHRP-ICMR funded project entitled "A diagnostic randomized controlled trial to study to validate novel DBS-based technology for prognosis and screening for leukemia transcripts" sanction ref no EM/Dev/NHRP-2023-0001854 (e office-179369), is ongoing with completed preliminary findings, with 100% concordance with sensitivity and specificity.
 - Device- NA
 - Vaccines-NA
 - Therapeutics- NA
 - Data for decision-making (Any registries or any other form of data collection for decision-making)- NA
 - Improved Clinical or Public Health Care- NA
 - Programme Support- NA
 - Any Other

II-Detailed Information Template: Research

A.Intramural Research Projects

A.1 Completed Intramural Research Projects in FY 2025-26

P.S.: Objectives of the project will not be considered as outcomes

S.No.	Intramural Project Grant ID	Project Title	Project Domain (CD/NCD/RCN/Others)	Project Area (4 Ds)	Major Outcomes (Bullet Points for Policy and Practices/ Publications Technologies/Products developed from the project)	Collaborating Institutes
1.	56/05/2022-Hae/BMS	Identification of novel synergistic inhibitors by studying differences in sensitivity towards pathway regulators and triple inhibitors of I3K/Akt/mTOR axis in T cell ALL	NCD	Descriptive	1. Role of synergistic inhibition is proved superior to isolated inhibition in the PI3kinase Akt and mTOR pathway in T-ALL. 2. GSK690693 the Akt inhibitor showed the most effective IC50 in all the three cell lines as compared to other inhibitors. 3. Perifosine showed the least effective drug with least inhibitory effects in all the three cell lines as compared to others. Patent Applied to ICMR-HQ-"Method for three-dimensional (3D) tissue culture model using patient-derived leukemia cell lines."	Department of Pediatrics, VMMC & Safdarjung Hospital, New Delhi

A.2 Case Study on Best (One) project completed (based on its translational potential with supporting documents, including high-resolution images)- NA

1. Background (100 words)

Provide a brief description of the problem or unmet need being addressed. Outline the broader context, including disease burden, public health relevance, or existing knowledge gaps. Clearly explain why this research was important and how it addresses a critical need.

2. Research Undertaken / Key Outputs (100 words)

Present an overview of the study or project, including its design, approach, and setting. Describe any key innovations, technologies, or methodologies that were used. Summarise the major findings or outputs, such as publications, products, diagnostics, guidelines, datasets, or patents.

3. Impact (100 words)

Describe the demonstrated or potential impact of the work. This may include its influence on policy or programmes, clinical or public health applications, technology transfer or commercialisation, and contributions to capacity building or system strengthening. Include any measurable outcomes, where available.

4. Implications for the Future (50 words)

Highlight the potential for scale-up or replication of the work in other settings. Outline the next steps, such as further validation, deployment, or partnerships. Conclude with the long-term relevance of the work for health systems and future research.

A.2.1 Ongoing Intramural Research Projects from ICMR

P.S.: Objectives of the project will not be considered as outcomes

S.No.	Intramural Project Grant ID	Project Title	Project Domain (CD/NCD/ RCN/Others)	Project Area (4 Ds)	Major Outcomes (Bullet Points for Policy and Practices/ Publications Technologies/Products developed from the project)	Collaborating Institute
1.	Intramural Ignition Grant (INTR-IG- NICHDR/13/2023)	Development of a 3D tumor model to validate the therapeutic potential of targeting immunogenic cell death, angiogenic factors, and their regulators in drug - resistant T -ALL	NCD	Development	1. Role of ICD and angiogenesis in an effective in-vitro 3D model in drug-resistant leukemia 2. Development of a validated 3-D model for therapeutic screening and pharmacological testing in drug-resistant leukemia 3. Proof of concept that leukemic cells become more immunogenic after induction of ICD, thus paving the role of the use of novel chemotherapeutic drugs in low-resource settings.	Department of Pediatrics, VMMC and Safdarjung Hospital

2.	Sanction ref no EM/Dev/NHRP-2023- 0001854 (e office-179369)	A diagnostic randomized controlled trial to study to validate novel DBS-based technology for prognosis and screening for leukemia transcripts	NCD	Development	1. Field validation study for a novel DBS (Dried blood spot) based kit (patent applied by ICMR) for leukemia transcript determination	1. Department of Pediatrics, AIIMS Bhubaneswar 2. Department of Pediatrics, AIIMS Jodhpur, 3. Department of Pediatrics, VMMC & Safdarjung Hospital, New Delhi 4. Department of Hematology, VMMC & Safdarjung Hospital, New Delhi
3.	Intramural Ignition Grant (INTR-IG-2023-02-0015)	Identification of Risk Factors of Gallbladder Cancer and Its Hotspot mapping in Delhi NCR: A Pilot Study (Ongoing)	NCD	Descriptive	1. Identification of geographic hotspots with a higher incidence of GBC cases through GIS mapping. 2. Identification and assessment of potential risk factors associated with GBC in the identified hotspots, which may be targeted for the implementation of intervention strategies to prevent and control GBC in the future. 3. Identification of possible contaminants or factors in potable water associated with GBC within hotspots, providing critical information for public health measures. 4. Development of a prediction model for the identification of GBC cases by screening the high-risk population of Delhi NCR.	AIIMS New Delhi. VMMC & Safdarjung Hospital

A.2.2 New Intramural Research Projects (2025-26)

S.No.	Intramural Project Grant ID	Project Title	Project Domain (CD/NCD/RCN/Others)	Project Area (4 Ds)	Major Outcomes (Bullet Points for Policy and Practices/ Publications, Technologies/Products developed from the project)	Collaborating Institute
1.	INTR-IG/NICHDR/7/2025(e-office No. 260544)	Identification of Fast Bone Losing Perimenopausal Women and Bone Loss Prediction using Machine-Learning Model: A Prospective Longitudinal Multicentric Study	RCN	Discovery	Initiated	1. ICMR-NIHR, Bhubaneswar 2. PGI, Chandigarh

B. Extramural Projects Received by ICMR Institutes

B.1) Completed Extramural Research Projects (Not ICMR) received from National/International Agencies

S.No.	Funding Agency	Project Title	Project Domain (CD/NCD/RCN/Others)	Project Area (4Ds)	Collaborating Institute	Major Outcomes (Bullet Points for Policy and Practices/ Publications Technologies/Products developed from the project)
1.	DST	Study on relationship between air pollution exposure of pregnant women and epigenetic changes mediated by AhR/CYP1A signaling pathway with the risk of intrauterine growth restriction (IUGR)	NCD	Descriptive	VMMC Safdarjung Hospital, New Delhi	- The majority of IUGR patients were from South Delhi district, reporting a very high average of PM2.5 and PM10 levels. - More women were involved in smoking (active and passive), in IUGR group vs AGA (86.54% vs 44.77%, p<0.001) - Most of the PAHs (particularly Naphthalene, Anthracene, Pyrene, Fluoranthene & Phenanthrene) were significantly higher in the maternal blood, placenta and cord blood of IUGR cases vs AGA cases.

2.	DST	Comparative Proteomic analysis to discover novel plasma biomarkers for early detection, surveillance and prognostication of Atrial fibrillation in patients with Rheumatic heart disease.	NCD	Descriptive	AIIMS Delhi	- Identified potential biomarker candidates with significant differential expression amongst our study groups – RHD+AF, RHD+NSR and Healthy controls. - The identified proteins include immunoglobulin peptides, amyloid proteins, immune-response, and thrombosis-related proteins. - Apoprotein A4 is downregulated in RHD patients with AF
3.	DHR–funded Grant in Aid	Digital Health Intervention to enhance self-management of Metabolic Syndrome (MetS) among adults living in urban poor settings	NCD	Development	FHTS	- Digital health intervention is likely to be feasible and well accepted among adults with MetS in low-resource urban settings. - An iterative approach that refined the intervention to suit the target population, making the program user- friendly and more likely to keep people interested and using it. - A human-centered digital intervention to help people in urban poor settings, such as urban slums, with limited resources to self-manage Metabolic Syndrome and enhance their overall well-being. - Digital application I-HEAL MetS developed

B.2) Ongoing Extramural Research Projects received from National/International Agencies

S.No.	Funding Agency	Project Title	Project Domain (CD/NCD/ RCN/Others)	Project Area (4Ds)	Collaborating Institute	Major Outcomes (Bullet Points for Policy and Practices/ Publications Technologies/Products developed from the project)
1.	CSIR-Aspire Grant Ref. 37WS (065)/2023-24/EMR- II/ASPIRE	Exploring autophagy, angiogenesis and tumor micro-environment in therapeutic resistance in MLL rearranged Leukemia	Childhood leukemia	VMMC & Safdarjung Hospital, New Delhi	VMMC & Safdarjung Hospital, New Delhi	Cell lines established with a 3D cell culture model for leukemia and autophagy in process
2.	ICMR (Extramural)	OMNIVEC-India: Designing and implementing a digital OMNI-channel Community Engagement and Risk Communication intervention for prevention and control of Vector- borne Diseases across India	Vector-Borne Disease	Development	Department of Health & Family Welfare, Punjab	The study showed moderate awareness about Dengue, but found the following critical gaps: • Low recognition of severe dengue signs. • Misconceptions on transmission. • Very low risk perception leading to complacency. • Current communication: limited to ASHA visits & interpersonal channels. • Digital IEC absent; local leaders play little role. • Community relies heavily on ASHAs/ANMs for health info.

3.	DBT	Proteomic analysis of cardiac tissue of atrial fibrillation patients with Rheumatic heart disease to understand the pathophysiology and to identify candidate biomarkers for diagnostic and therapeutic applications	Non-Communicable Diseases	Descriptive	AIIMS Delhi	Identified a set of 15 proteins—namely MYH14, MYL2, MYH11, MYH10, MYH9, POSTN, DPT, CILP, LYZ, CA2, CNN2, and PF4 etc. that demonstrated significant differential expression between the AF and NSR patient groups.
----	-----	--	---------------------------	-------------	-------------	---

B.3) New Extramural Research Projects received from National/International S& T Agencies

S.No.	Funding Agency	Project Title	Project Domain (CD/NCD/RCN/Others)	Project Area (4Ds)	Collaborating Institute	Major Outcomes (Bullet Points for Policy and Practices/ Publications Technologies/Products developed from the project)
NA						

B. Capacity building and training, Masters/PhD

S.No	Type & Name of Programme	Ongoing	Completed
1.	Masters	-	-
2.	Ph.D.	4	-
3.	Ph.D. (AcSIR-FMR)	3	-
4.	Post-Doctoral Fellow	3	1
5.	Others (M.Sc. Dissertation)	11	8

D. Workshop/ Training

S.No.	Type & Name of Programme	List of programmes	Number of Participants in each	Nature of participants (researchers/ state officials/ ANM/ASHA etc.) in each
1	Certificate Course	NA		
2	Workshop	JBI Comprehensive Systematic Review Training Program (CSRTP)	40	Clinicians, Researchers, and PhD Scholars
3	Training	Two-Day training cum workshop- Two-Day Hands-on Workshop on DBS Training	32	Researchers, Phlebotomists, Pathologists, Laboratory technicians, Clinicians, Oncologists

E. List of publications

Provide Annexure with Publication List – Enclosed- Annexure 1

S. no.	DOI	Title	Year	Journal/Book	IF	Type of article (Original research/Systematic Review/ Meta-analysis/ Review/ Correspondence/Commentary/Book Chapter)	Authors	Authorship (First/Last/ Corresponding)
--------	-----	-------	------	--------------	----	--	---------	--

F. Services provided

Validation of Technologies

S.No.	Name of Technology	Area (CD/NCD/RCN)	One line description	Firm/Company	Recommended/Not Recommended
-------	--------------------	-------------------	----------------------	--------------	-----------------------------

	NA
--	----

Diagnostic service provided

S.No.	Name of Disease/Health Condition	Type of Testing	Number of samples
1.	Pediatric hematological disorders- leukemia and MPNs	Molecular transcript as per the WHO classification of hematolymphoid malignancies. Panels include the B-ALL panel, the T-ALL panel, the BCR-ABL quantitative and qualitative testing, and the Pediatric leukemia panel.	2039 samples for peripheral blood and bone marrows
2.	Skin Diseases: Infective, Chronic conditions, Autoimmune, Premalignant, Benign & Malignant tumors Skin Cases referred from Madan Mohan Malviya Hospital, Delhi, & GMC Aurangabad, Maharashtra	Histopathology Histochemistry Immunohistochemistry	Approx. 3000/year

Patient Care Provided

S.No.	Name of Disease/Health Condition	Type of Support	Number of patients
		NA	

G. Role played during disasters, emergency situations, outbreaks - NA

H. Contributions to policy/ guideline (Participation as an Expert should not be included). Only research.

S.No.	Research output included in the Policy/ Programme	Name (policy/ Programme)	Type of Document (Guideline/ Model/ Clinical etc.) (Provide Link)
NA			

I. Innovations/ patents

S.No.	Name of Technology/Product	Area (CD/NCD/RCN)	Number of Patents (filed)	Number of Patents (Granted)	Tech transferred	Tech Commercialized (Company Name)	TRL*	Test/Manufacturing License
1.	PATENT filed-- "Method for three- dimensional (3D) tissue culture model using patient-derived leukemia cell lines."	In vitro culture model for childhood leukemia for translational studies	Application filed to ICMR- HQ, IPR- Patent Mitra Division	Awaited	Awaited	Awaited	TRL-4	Awaited

****TRL Reference***

TRL Level Definition

TRL 1 Basic principles observed and reported

TRL 2 Technology concept and/or application formulated

TRL 3 Analytical and experimental critical function/proof-of-concept

TRL 4 Technology/component validation in laboratory environment

TRL 5 Technology/component validation in relevant environment

TRL 6 System/subsystem model or prototype demonstration in a relevant environment

TRL 7 System prototype demonstration in an operational environment

TRL 8 Actual system completed and qualified through test and demonstration

TRL 9 Actual system proven through successful mission operations

J. One best case study of a technology/ product transferred or commercialized as Annexure, If any:

1. Background (100 words)

Provide a brief description of the problem or unmet need that led to the development of the technology. Explain the public health or clinical relevance, along with any existing limitations in current solutions. Clearly state why there was a need for developing this technology.

2. Technology Developed / Key Features (100 words)

Describe the technology in simple terms, including what it is and how it works. Provide an overview of its development, including the approach and setting. Highlight the key features, innovations, or advantages over existing solutions. Summarise important outputs such as prototypes, validated tools, patents, publications, or regulatory approvals, if any.

3. Impact and Use (100 words)

Explain how the technology is being used or has the potential to be used in real-world settings. This may include clinical application, public health programmes, or field deployment. Mention any technology transfer, commercialisation, partnerships, or adoption by stakeholders. Include measurable outcomes or benefits, where available.

4. Future Potential (50 words)

Outline the scope for scale-up, wider deployment, or adaptation in different settings. Describe the next steps, such as further validation, regulatory pathways, manufacturing, or partnerships. Highlight the long-term relevance and how the technology could contribute to improving healthcare delivery or outcomes.

High Resolution picture

K. Dissemination (Exhibitions/ Conferences/ Seminars) Organized.

S.No.	Title	Type	National /International	Number of Participants
	NA			

L. Awards and honors (Not Individual but that any programme/ institute level recognition) To be Highlighted.

S.No.	Name of Award/s	National/International	Name of Programme/ Institute
NA			

M. Infrastructure developed in FY 2025-26

Infrastructure Type (e.g., Lab, MRHRU, Animal Facility, Equipment, Building, Satellite Center)	Facility Name / Description	Location	Purpose	Status (Planned/Ongoing/Completed)	Start Date	Funding Source	Remarks
NA							

N. GoI initiative (High resolution photos)

S.No.	Name of Initiative	Activities & Venue	Number of Participants
1.	National Sports Day	-	-
2.	Hindi Pakhwada	18-09-2025 to 24-09-2025 Essay competition, poster, and general knowledge competition ICMR-NICHR	45
3.	Swachhta Abhiyan	22-09-2025 to 03-10 -2025 Shramdaan, Health Camp, Plantation Drive, Felicitation of Safai Mitra's ICMR-NICHR	60
4.	International Yoga Day	-	-
5.	Women's Day	-	-
6.	Vigilance Awareness Week	Staff participated in an online pledge-taking ceremony	150
7.	Karmayogi	-	-

P.S. Please provide high-resolution photographs related to research/major initiatives/technologies/major events/activities/ community engagement/field visits, may be provided with captions (detail of activity & place)- Attached in annexure 2

Annexure 1 – Publication list 2025- 26

S. no.	DOI	Title	Year	Journal/Book	IF	Type of article	Authors	Authorship
1	10.1007/s11306-025-02268-6	Identification of altered metabolites in Rheumatic Heart Disease patients with atrial fibrillation and normal sinus rhythm using untargeted LC-MS metabolomics	2025	Metabolomics	3.5	Original research	Das S, Shruti S, Kumar Y, Gupta S, Jayamon A, Srishty, Sharma G	Corresponding Author
2	10.4103/idoj.idoj_1200_24	Limping Child with a Painful Sweaty Blue Patch on Foot: A Case of Eccrine Angiomatous Hamartoma	2026	Indian Dermatol Online J	1.9	Case Report	Srivastava P, Khunger N, Sharma S	Co Author
3	10.1111/jpc.16499	Nail sign: Harbinger to systemic disease	2025	J Paediatr Child Health	1.4	Case Report	Sharma S and Sharma YP	First
4	10.1111/ijd.70288	An Unusual Case of Juvenile Dermatomyositis Complicated by Macrophage Activation Syndrome	2026	Int J Dermatol	3.2	Clinical correspondence	Yadav K, Verma P, Srivastava P, Khunger N, Sahoo B, Shruti S	Co-author
5	10.4103/idoj.idoj_626_24	Cerebrotendinous Xanthomatosis: A Reversible Rarity if	2025	Indian Dermatology Online Journal	1.9	Case Report	Suresh P, Dev PP, Khunger N, Sharma S	Co-author

		Caught on Time						
6	10.4103/idoj.idoj_1134_24	Not Just a Bleeding Scar: The Mystery of Cesarean Scar Endometriosis	2025	Indian Dermatology Online Journal	1.9	Case Report	Harsh FNU, Srivastava P, Khunger N, Sharma S, Krish K	Co-author
7	10.4103/JVBD.JVBD_205_24	Reworking the treatment of Indian Post kala-azar dermal leishmaniasis: A two-step therapy	2025	Journal of Vector Borne Diseases	1.2	Research Article	Kathuria S, Gautam Y, Khunger N, Sharma S, Singh R	Co-author
8	10.25259/IJDVL_542_2025	Localised cutaneous siderosis following intravenous ferric carboxymaltose infusion: An underreported complication	2025	Indian J Dermatol Venereol Leprol	2.9	Case Report	Misri R, Sharma S, Gaurav V	Co-author
9	10.4103/ijstd.ijstd_142_24	From clinical clues to histologic truth: A case of condyloma lata	2025	Indian Journal of Sexually Transmitted Diseases and AIDS	NA	Case Report	Rathi P, Srivastava P, Khunger N, Sharma S, Dash A	Co-author
10	10.1111/pde.15974	Chronic Tender Palmar Plaque in a 15-Year-Old Boy	2025	Paediatric Dermatology	1.2	Case Report	Misri R, Shruti S, Gaurav V	Co-author
11	10.7759/cureus.101061	A Systematic Review of Occupational Cancers in the Indian Sub-continent	2026	Cureus	1.4	Systematic Review	Reena Bhardwaj, Neeraj Kumar, Swati Joshi, Ayushi Gupta, Souvik Manna	First and Corresponding Author
12	10.26434/chemrxiv-2025-	Quantification of Common NSAIDs in FDCs with	2025	ChemRxiv	-	Original	Ekta Goel, Dr. Jyoti Singh	Corresponding

	lxwvr	Paracetamol Using UV Spectrometry and Simultaneous Equation Method						
13	10.17605/OSF.IO/S4ERB	Newborn Screening in India (1985 - 2025): A Comprehensive Scoping Review Protocol	2025	Open Science Framework	-		Jyoti Singh	First author
14	10.18203/23201770.ijrcog20253536	Leptin and LH/FSH Ratio as Independent Predictors of PCOS in Normoglycemic Women	2025	International Journal of Reproduction, Contraception, Obstetrics and Gynecology	-	Original	Jyoti Singh and Anju Jain	First author
15	10.1186/s44247-026-00248-x	Design and develop I-HEAL MetS platform to enhance self-management of metabolic syndrome among adults living in urban slums	2026	BMC Digital Health	-	Original Research	Ashish Joshi, Sandeep Agrawal, Ashoo Grover, Bhavya Malhotra, Mansi Gauniyal, Shravani Rajkhowa, Bhavika Rishi	Co-author
16	10.1111/ijlh.70013	Pediatric Severe Eosinophilia: Etiological Spectrum, Diagnostic Algorithm, and Case-Based Insights from a Tertiary Care Centre	2026	International Journal of Laboratory Hematology	2.3	Original Research	N Goel, S Mehndiratta, S Batra, A Singh, P Prabhakar, A Misra, B Rishi, et al.	Corresponding
17	10.3389/fonc.2025.1663975	Pediatric tumor microenvironment:	2025	Frontiers in Oncology	6.9	Review	NG George, B Rishi, H Dhanda, GT Joseph, SK Swain, M Kaur,	Co-author and corresponding

		developmental dynamics and therapy resistance					et al.	
18	10.3390/onco6010002	Tumor Microenvironment: Current Understanding and Therapeutic Implications in Adult and Pediatric Cancers	2025	Onco	-	Review	Satyendra Batra, Prashant Prabhakar, Debabrata Mohapatra, Noreen Grace George, Neha Goel, Bhavika Rishi, Aroonima Misra, Amitabh Singh	Co-author and corresponding
19	10.3389/fpub.2025.1710603	Design of an implementation research study for a digital omnichannel community engagement and risk communication intervention for the prevention and control of vector-borne diseases in India: the OMNIVEC-India study protocol	2026	Frontiers in Public Health	3.4	Original research article	Rodrigues R, Dhatrak A, Bal M, Nongrum MS, Kumar N, Sarkar R, Agrawal T, Mundra A, Praharaj I, Singh J, Zode M, Roy S, Kandpal V, Lyngdoh T and Omnivec Study Team (2026)	Co-author
20	10.1093/trstmh/traf118	Detection of subpatent malaria among febrile mobile and migratory population individuals: a strategy for malaria elimination	2026	Transactions of The Royal Society of Tropical Medicine and Hygiene	1.5	Original research article	Kaura T, Mewara A, Devi S, Singh N, Takkar J, Kumar N, Sehgal R, Grover GS	Co-author
21	10.1038/s41598-025-01448-7	Repurposing FDA approved drugs for psoriasis indications	2025	Scientific Reports	3.9	Original research	Choudhary S, Khan NS, Saxena P, Sahu P, Pradhan D, Singh H, Thomas G, Kumar N	Corresponding author

		through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches						
22	10.1007/s12291-024-01182-3	A new machine learning approach for actual calcium measurement	2025	Indian Journal of Clinical Biochemistry	1.6	Original Research	Kumari, Suchitra; Nayak, Saurav; Mangaraj, Manaswini	Corresponding
23	10.1097/meg.0000000000002971	FoxP3-positive T regulatory cells and its effector mechanisms in Crohn's disease: an immunohistochemical and image morphometric analysis on endoscopic mucosal biopsies	2025	European Journal of Gastroenterology & Hepatology	1.8	Original Research	Patra, Susama; Chaudhary, Shalini; Samal, Subash Chandra; Ayyanar, Pavithra; Padhi, Somanath; Nayak, Hemanta Kumar; Satapathy, Amit Kumar; Nayak, Saurav; Sahu, Ajit; Parida, Tapaskanti	Co-Author
24	10.4314/ahs.v25i1.36	Cytokine and immune cell interaction in immune-inflammatory response during crisis event in sickle cell disease	2025	African Health Sciences	1.1	Original Research	Patel, Suprava; Nayak, Saurav; Chandrakar, Diksha; Wasnik, Preetam N; Jagzape, Tushar B; Mohapatra, Eli; Nanda, Rachita; Shah, Seema	Co-Author
25	10.6026/973206300211069	A machine-learning clustering approach for reference interval estimation of liver enzymes from hospital laboratory big-data	2025	Bioinformation	1.9	Original Research	Dash, Prakruti; Nayak, Saurav	Co-Author
26	10.1007/s12291-024-01182-3	Exploring the Association	2025	Indian Journal	1.6	Original	Panda, Chhabhi Rani; Mangaraj,	Corresponding

	1-025-01344-x	of MMP-7 Promoter Site Single Nucleotide Polymorphism with Risk of Diabetic Nephropathy		of Clinical Biochemistry		Research	Manaswini; Panda, Sandip Kumar; Kumari, Suchitra; Saharia, Gautom Kumar; Nayak, Saurav	
37	10.6026/973206300213941	Ensemble neural network modelling for stratified HbA1c prediction: Integrating past glucose measurement as a predictor of glycaemic control	2025	Bioinformation	1.9	Original Research	Dash, Prakruti; Farzia, Kasala; Priyadarshini, Dharashree; Nayak, Saurav	Corresponding
28	PMID: 41459186	Analyzing the Utility of Pooled Sera as Internal Quality Control for Immunoassay Parameters by an EWMA-backed Statistical Mechanism (e-PSQC): A Comparison with Commercially Available Material and Westgard Rules	2025	EJIFCC	1.09	Original Research	Dash, Prakruti; Nayak, Saurav; Roy, Tanushree	Corresponding
29	10.1093/tropej/fmag003	Newborn screening in an Eastern Indian province: prevalence and trends from a burgeoning newborn screening unit	2026	Journal of Tropical Pediatrics	1.1	Original Research	Saharia, Gautom Kumar; Nayak, Saurav; Mangaraj, Manaswini; Som, Tapas Kumar; Mohanty, Pankaj Kumar; Sahoo, Tanushree	Corresponding
30	PMID: 41659300	Linking Glomerular Endothelial Dysfunction	2026	EJIFCC	1.09	Original Research	Farzia, Kasala; Dash, Prakruti; Saharia, Gautom Kumar; Jena,	Co-Author


		with Urinary KIM-1, sFlt-1, Serum IL-10, and Regulatory T Cells in Preeclampsia					Saubhagya Kumar; Nayak, Saurav	
31	10.34763/jmotherandchild.20263001.d-25-00031	Combination of Markers, Including hsCRP, TGFβ 1, IL-6, and T-regs, and their Predictive Value as Early Warning Signs for Preeclampsia: Insights from a Tertiary Care Medical Centre in Eastern India	2026	Journal of Mother and Child	1.10	Original Research	Dash, Prakruti; Koppisetty, Bharath Kumar; Jena, Saubhagya Kumar; Nayak, Saurav	Co author
32	10.1007/s12070-026-06477-w	Submandibular gland excision in oral squamous cell carcinoma: is it a necessity?	2026	Indian Journal of Otolaryngology and Head & Neck Surgery	0.4	Original Research	Shaikh, Zaid; Parida, Pradipta Kumar; Karakkandy, Vinusree; Bondada, Charishma; Hameed, Hiba; Krishnan, Aravind; Chappity, Preetam; Pradhan, Pradeep; Sarkar, Saurav; Samal, Dilip Kumar	Co author
33	PMID: 42006498	Triple Point Pooled Sera (TriPPS) QC for Laboratory Analyte Error Detection: A Machine Learning based Quality Control in Laboratory	2026	EJIFCC	1.09	Original Research	Dash, Prakruti; Rout, Sudeshna; Koppisetty, Bharath Kumar; Panda, Chhabi Rani; Priyadarshini, Dharashree; Roy, Tanushree; Nayak, Saurav	Corresponding
34	https://doi.org/10.3389/fonc.2025.103389	Hypoxic microenvironment in	2025	Frontiers in Oncology	3.3	Review	Sureka N, Maheshwari R, Agravat A, Singhal S, Zaman S,	Corresponding

	026.1771365	cancer: role in metabolic reprogramming.					Rishi B, Siraj F, Zaheer S, Misra A	
35	https://doi.org/10.3389/frhem.2026.1709697	Evaluating role of TNF- α in tyrosine kinase inhibitors-treated chronic myeloid leukemia.	2026	Frontiers in Hematology	1.2	Original Research	Joseph GT, Swain SK, Dhanda H, Kushwaha N, Kumari P, Khushalani MP, Kumar R, Noor B, Zaheer S, Jain A, Jain A	Corresponding
36	https://doi.org/10.3389/fphar.2025.1714797	Validation of diagnostic screening test for pharmacogenomic targets for thiopurine drugs in Indian pediatric acute lymphoblastic leukemia patients	2025	Frontiers in Pharmacology	4.8	Original Research	Joseph GT, Swain SK, Somwanshi T, Singh A, Kaur M, Kamal R, Dhanda H, Kumar P, Kaushik U, Noor B, Sharma S	Corresponding
37	https://doi.org/10.1007/s12288-025-02178-6	Beyond Hemoglobinopathies: Non-Hemoglobinopathy Causes of Transfusion-Dependent Anemia in Children.	2025	Indian Journal of Hematology and Blood Transfusion	0.9	Original Research	Misra A, Goel N, Prabhakar P, Dandriyal R, Rishi B, Singh A, Baruah R, Chopra N, Mehndiratta S, Ray S, Das S	Joint and first
38	https://doi.org/10.1007/s12088-024-01373-9	Current trends and advances in nanoplatforms-based imaging for cancer diagnosis	2025	Indian Journal of Microbiology.	1.6	Review	Umadevi K, Sundeep D, Vighnesh AR, Misra A, Krishna AG	Co Author

Annexure 2 - Hindi Pakhwada 2025



Swachhta Abhiyan 2025



Community engagement through MRHRU Bhunga, Punjab

